CeceliaPatriceKaneMD

PubMed

• 86 citations
  Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
  Sheldon H. Preskorn, Cecelia P. Kane, Kasia Lobello, Alice I. Nichols, Rana Fayyad, Gina Buckley, Kristen Focht, Christine J. Guico-Pabia> ;The Journal of Clinical Psychiatry. 2013 Mar 13
• 8 citations
  Open-Label Treatment with Desvenlafaxine in Postmenopausal Women with Major Depressive Disorder Not Responding to Acute Treatment with Desvenlafaxine or Escitalopram
  Claudio N. Soares, Michael E. Thase, Anita H. Clayton, Christine J. Guico-Pabia, Kristen Focht, Qin Jiang, Susan G. Kornstein, Phillip T. Ninan, Cecelia P. Kane> ;CNS Drugs. 2011 Mar 1
• 45 citations
  Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period...
  Alice I. Nichols, Kristen Focht, Qin Jiang, Sheldon H. Preskorn, Cecelia P. Kane> ;Clinical Drug Investigation. 2011 Jan 1
• 41 citations
  Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder.
  Claudio N. Soares, Michael E. Thase, Anita H. Clayton, Christine J. Guico-Pabia, Kristen Focht, Qin Jiang, Susan G. Kornstein, Phil Ninan, Cecelia P. Kane, Lee S. Cohen> ;Menopause. 2010 Jul 1
• 8 citations
  Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
  Sujana Reddy, Cecelia P. Kane, Bruno Pitrosky, Jeff Musgnung, Philip T. Ninan, Christine J. Guico-Pabia> ;Current Medical Research and Opinion. 2010 Jan 1
• 55 citations
  Placebo-controlled study of fluvoxamine in the treatment of patients with compulsive buying.
  Philip T. Ninan, Susan L. McElroy, Cecelia P. Kane, Bettina T. Knight, Leah S. Casuto, Steve E. Rose, Frederick A. Marsteller, Charles B. Nemeroff> ;Journal of Clinical Psychopharmacology. 2000 Jun 1
• Join now to see all